SlidesetViral Hepatitis and Liver DiseaseInternational Viral Hepatitis Elimination Meeting (IVHEM) 2019Mortality from Liver Diseases Associated with Hepatitis B and C in the EU/EEA – Descriptive Analysis and Estimation of 2015 Baseline- O. MårdhView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Viral Hepatitis Elimination Meeting (IVHEM) 2019Use of the HBV Viral Load Medical Prescription as a Preliminary Assessment of HBV Infection Burden in New Caledonia: a 2014-2019 Retrospective Study- P. DényView Slideset
KKKenneth KabagambeSlidesetViral Hepatitis and Liver DiseaseInternational Viral Hepatitis Elimination Meeting (IVHEM) 2019Uganda’s Experience- Kenneth KabagambeView Slideset
MHEManal Hamdy El-SayedMD, PhDSlidesetViral Hepatitis and Liver DiseaseInternational Viral Hepatitis Elimination Meeting (IVHEM) 2019Monitoring and Testing, Introductory Lecture- Manal El-Sayed, MD, PhDView Slideset
MTMark TyndallMD, ScD, FRCPCSlidesetViral Hepatitis and Liver DiseaseInternational Viral Hepatitis Elimination Meeting (IVHEM) 2019Canada’s Experience with Needle Exchange Programs- Mark Tyndall, MD, ScD, FRCPCView Slideset
MNMichael NinburgMPASlidesetViral Hepatitis and Liver DiseaseInternational Viral Hepatitis Elimination Meeting (IVHEM) 2019WHA / Community Perspective on the Need for Simplification- Michael NinburgView Slideset
PEPhilippa EasterbrookBSc (Hons), MD, MPH, DTM&H, FRCPSlidesetViral Hepatitis and Liver DiseaseInternational Viral Hepatitis Elimination Meeting (IVHEM) 2019WHO / Perspective on the Simplification Strategies- Philippa Easterbrook, MD, FRCP, MPH, DTM&HView Slideset
JFJordan FeldMD, MPHSlidesetViral Hepatitis and Liver DiseaseInternational Viral Hepatitis Elimination Meeting (IVHEM) 2019Introduction of Simplification- Jordan Feld, MD, MPHView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019Levofloxacin Target Attainment Analysis in MDR-TB Patients: Time is Ripe for Proactive TDM - Mathieu BolhuisView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019Drug Effect of Clofazimine on Persistent Mycobacteria Explain an Unexpected Increase of Bacterial Load in Patients - Alan FarajView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019Population Pharmacokinetics of Linezolid in TB Patients: Dosing Regimens Simulation and Target Attainment Analysis - Charles PeloquinView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019PK-PD of Isoniazid Given at Different Doses Among Patients with MDR-TB with INH Resistance Mediated by inhA Mutations: Modeling Results from ACTG A5312 - Kamunkhwala GausiView Slideset
